TickerFacts.

Emmaus Life Sciences, Inc. (EMMA): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

$270.0K
Year ended 2025-12-31
$4.61M
Trailing 12 months to 2026-06-30
+57.3%
5-year compound annual growth
$3.57M2018-12-31: -$8.39M2019-12-31: -$4.44M2020-12-31: $28.0K2021-12-31: -$6.07M2022-12-31: -$6.53M2023-12-31: $3.57M2024-12-31: -$1.87M2025-12-31: $270.0K$270.0K
2018-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31$270.0Kn/m2026-03-31, From 2025-01-01
2024-12-31-$1.87Mn/m2026-03-31, From 2024-01-01
2023-12-31$3.57Mn/m2025-04-14, From 2023-01-01
2022-12-31-$6.53Mn/m2024-07-03, From 2022-01-01
2021-12-31-$6.07Mn/m2023-03-31, From 2021-01-01
2020-12-31$28.0Kn/m2022-03-31, From 2020-01-01
2019-12-31-$4.44Mn/m2021-08-10, From 2019-01-01
2018-12-31-$8.39Mn/a2021-01-25, From 2018-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$270.0Kn/m
Prelude Therapeutics Inc (PRLD)2025-12-31-$102.86Mn/m
Evommune, Inc. (EVMN)2025-12-31-$80.47Mn/m
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31-$123.80Mn/m
Jaguar Health, Inc. (JAGX)2025-12-31-$43.99Mn/m
CV Sciences, Inc. (CVSI)2025-12-31-$278.0Kn/m
Pyxis Oncology, Inc. (PYXS)2025-12-31-$79.91Mn/m
Precigen, Inc. (PGEN)2025-12-31-$107.31Mn/m
Prothena Corp Public Ltd Co (PRTA)2025-12-31-$213.75Mn/m

Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗